Developing new drugs to inhibit cancer cell growth
Official title: Multidisciplinary Investigation of Antitubulin Heterocycles using Synthesis, Biology, and Structural Analysis
Funded at Hobart and William Smith Colleges · NIH-10729604 · Data updated 2026-11-12
This study is working on new medicines that target a protein important for cancer cells to grow and survive, with the hope that these new treatments will be safer and more effective for patients than what we have now.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hobart and William Smith Colleges NIH-funded |
| Lab location | 1 site (Geneva, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $386,781 |
| NIH project number | 1R15CA274493-01A1 |
| Project ID | NIH-10729604 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with various types of cancer who may benefit from new therapeutic options.
✕Less likely to help
Patients who are not currently undergoing cancer treatment or those with non-malignant conditions may not receive any benefit from this research.
What this research studies
This research focuses on creating new drugs that target tubulin, a protein essential for cancer cell division and structure. By using a method called rational drug design, the team aims to develop novel compounds that can effectively inhibit tubulin polymerization, which is crucial for cancer cell survival. The research involves synthesizing new drug candidates and testing their effectiveness and safety against cancer cells. Patients may benefit from these new treatments that could potentially overcome the limitations of current cancer therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic cancer treatments.
How similar studies have gone: Previous research has shown promise in developing tubulin inhibitors, indicating that this approach has potential for success.
Where this research is happening
-
Hobart and William Smith Colleges
Geneva, United States Active
Researchers
- Principal investigator: Pelkey, Erin Thomas — Hobart and William Smith Colleges
- Study coordinator: Pelkey, Erin Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.